Sentences with phrase «challenge vaccine development»

«The high diversity found within the [TcI] strain may challenge vaccine development and treatment improvement, if the genetically different strains respond differently to particular medication.»

Not exact matches

This challenge has hindered dengue vaccine development for more than 60 years.

This makes the development of an effective vaccine to protect against infection, as well as antiviral therapy to combat already - existing infections, particularly challenging,» says Dr. Grant Hansman, a virologist who leads the CHS Research Group on Noroviruses at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and Heidelberg University.

Insights from human challenges reach far beyond drugs and vaccine development.

Like many types of bacterial pathogens, A. marginale has a huge variety of strains and is widely distributed geographically, which makes vaccine development challenging.

The symposium features presentations by Philippa Marrack and John Kappler talking on the T cell repertoire; William Paul on interleukin 4 as a prototypic immunoregulatory cytokine; Timothy Springer on lymphocyte trafficking; Pamela Bjorkman on structural studies of MHC and MHC - related proteins, and Jack Strominger on peptide presentation by class I and II MHC proteins; Thierry Boon on genes coding for tumor rejection antigens, including the first tumor antigen, MAGE - 1; and Philip Greenberg on the modification of T cells for adoptive therapy by retroviral - mediated gene insertion Since then, the symposia series has attracted leading immunologists in the cancer vaccine and antibody fields, providing them with a comprehensive view of the promises and challenges in the development of cancer immunotherapies.

In just the last 6 years the EID outbreaks of MERS, Ebola, Zika, CHIKV as examples have underscored the importance of rapid vaccine development and deployment capabilities to meet EID challenges, as well as growing appreciation for creativity and flexibility in clinical trial design.

With this comprehensive approach, TRANSVAC2 functions as a leverage and innovation catalyst between all stakeholders involved in vaccine R&D in Europe, and contributes to the development of effective products to address European and global health challenges.

«We see a Zika challenge model as really beneficial for not only vaccine development,» Durbin said, «but also to learn more about Zika itself.»

Vaccine development for DENV is challenging in that the vaccine must induce long - lasting immunity against all four DENV serotypes (DENV1 - 4), as pre-existing immunity against a heterologous serotype may contribute to severe dengue disease (DHF Vaccine development for DENV is challenging in that the vaccine must induce long - lasting immunity against all four DENV serotypes (DENV1 - 4), as pre-existing immunity against a heterologous serotype may contribute to severe dengue disease (DHF vaccine must induce long - lasting immunity against all four DENV serotypes (DENV1 - 4), as pre-existing immunity against a heterologous serotype may contribute to severe dengue disease (DHF / DSS).

Moving the Needle provides quarterly updates from PATH's Center for Vaccine Innovation and Access (CVIA) on our vaccine development efforts, as well as related supporting work, such as developing human challenge models, building capacity of developing - country vaccine manufacturers, and evaluating new adjuvants and other novel vaccine technoVaccine Innovation and Access (CVIA) on our vaccine development efforts, as well as related supporting work, such as developing human challenge models, building capacity of developing - country vaccine manufacturers, and evaluating new adjuvants and other novel vaccine technovaccine development efforts, as well as related supporting work, such as developing human challenge models, building capacity of developing - country vaccine manufacturers, and evaluating new adjuvants and other novel vaccine technovaccine manufacturers, and evaluating new adjuvants and other novel vaccine technovaccine technologies.

Dr Odile Leroy, Executive Director of the European Vaccine Initiative (EVI) and coordinator of TRANSVAC2, said: «The TRANSVAC2 activities will further strengthen the vaccine R&D infrastructure in Europe and will thereby accelerate the development of effective vaccines that are urgently needed to address global health challenges&Vaccine Initiative (EVI) and coordinator of TRANSVAC2, said: «The TRANSVAC2 activities will further strengthen the vaccine R&D infrastructure in Europe and will thereby accelerate the development of effective vaccines that are urgently needed to address global health challenges&vaccine R&D infrastructure in Europe and will thereby accelerate the development of effective vaccines that are urgently needed to address global health challenges».

TRANSVAC is a new infrastructure project - funded by the European Commission in the context of Horizon 2020 - that aims to accelerate the development of effective vaccines urgently needed to address European and global health challenges with the ultimate goal to build an efficient and sustainable collaboration of experts and facilities to catalyse vaccine research in Europe.

Malaria parasites have a complex life cycle and high variability which has made the development of a vaccine a real challenge.